Notification about latest news from us.
Trump's new 100% tariff on imports aims to lower drug prices and boost domestic manufacturing, though it carries significant implications for consumers and companies.
Trump announces new agreements with pharmaceutical firms to reduce drug prices in the US, aligned with prices in other developed countries.
The US and UK announce a zero tariff deal on pharmaceuticals, resulting in increased NHS spending on medicines by 25%.
Pfizer secures a $10 billion acquisition of Metsera, concluding a heated bidding war against Novo Nordisk.
Health authorities and multiple states ban Coldrif; DEG contamination tied to child deaths; investigations and factory inspections underway.
TrumpRx aims to reduce prescription medication costs for Americans but faces skepticism over its potential effectiveness.
Singapore's pharmaceutical companies seek exemption clarity from new US tariffs, signaling potential impacts on $3.1 billion exports.
Trump's latest tariffs target pharmaceuticals, furniture, and trucks, imposing steep duties to bolster U.S. manufacturing starting October 1.
Trump's plan to impose 200% tariffs on imported drugs could lead to higher prices and shortages for consumers.
The US expects to generate $50 billion in monthly tariff revenues as new import levies begin to take effect.
By clicking send you'll receive occasional emails from newsletters about this topic.